XAIR Beyond Air, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1641631 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY41.2%
TTM net income YoY9.1%
TTM EPS YoY168.8%
Revenue 3-yr CAGR201.8%
Net income 3-yr CAGR—
Margins
Gross margin10.0%
Operating margin-321.7%
Net margin-407.3%
FCF margin-259.0%
EBITDA margin-282.6%
Returns
ROE-369.6%
ROA-99.3%
ROIC (approx.)-1,404.8%
Asset turnover0.24x
Leverage & solvency
Liabilities / assets83.1%
Debt / equity0.00x
Current ratio3.67x
Interest coverage-4.95x
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-40.7%
Payout ratio—
Capex / revenue18.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.32M | $1.77M | $1.91M | $2.19M | $1.82M | $1.76M | $1.15M | $1.07M |
| Cost of revenue | $2.13M | $1.54M | $1.81M | $1.89M | $2.12M | $1.60M | $1.18M | $1.29M |
| Gross profit | $197,000 | $225,000 | $94,000 | $300,000 | -$298,000 | $156,000 | -$32,000 | -$215,000 |
| R&D expense | $1.58M | $1.96M | $2.28M | $2.43M | $2.45M | $3.09M | $3.26M | $3.00M |
| SG&A expense | $4.59M | $4.88M | $4.99M | $4.47M | $4.91M | $4.69M | $3.88M | $7.73M |
| Operating income | -$5.97M | -$6.61M | -$7.17M | -$6.60M | -$7.66M | -$7.62M | -$7.17M | -$10.95M |
| Interest expense | $1.50M | $1.49M | $1.24M | $1.09M | $639,000 | $548,000 | $580,000 | $549,000 |
| Pretax income | -$8.18M | -$8.15M | -$10.37M | -$7.63M | -$8.26M | -$8.08M | -$8.06M | -$13.33M |
| Net income | -$7.82M | -$7.93M | -$10.28M | -$7.34M | -$7.94M | -$7.69M | -$8.03M | -$13.03M |
| EBITDA | -$5.17M | -$5.81M | -$6.37M | -$5.80M | -$6.86M | -$6.82M | -$6.37M | -$10.15M |
| EPS (basic) | -3.76 | -11.00 | — | -0.85 | -24.98 | -30.67 | — | -2.96 |
| EPS (diluted) | -3.76 | -11.00 | — | -0.85 | -24.98 | -30.67 | — | -2.96 |
| Weighted avg. shares (diluted) | 2.08M | 721,328 | — | 8.62M | 317,829 | 250,747 | — | 4.40M |
| Balance sheet | ||||||||
| Cash & equivalents | $5.40M | $5.51M | $6.74M | $6.64M | $9.70M | $4.98M | $4.67M | $4.60M |
| Short-term investments | $5.65M | $4.30M | $4.90M | $5.02M | $996,000 | $1.49M | $2.25M | $6.35M |
| Receivables | $1.45M | $1.14M | $1.09M | $1.15M | $892,000 | $804,000 | $710,000 | $639,000 |
| Inventory | $1.19M | $1.29M | $1.41M | $1.76M | $2.23M | $2.43M | $2.42M | $2.38M |
| Current assets | $26.63M | $22.85M | $24.77M | $25.56M | $18.59M | $14.99M | $16.02M | $19.34M |
| PP&E, net | $7.63M | $7.92M | $8.25M | $8.50M | $9.39M | $10.19M | $11.01M | $11.65M |
| Intangibles | — | — | $1.02M | — | — | — | $1.22M | — |
| Total assets | $36.26M | $32.89M | $35.38M | $36.77M | $30.96M | $28.11M | $30.06M | $34.14M |
| Current liabilities | $7.25M | $6.91M | $6.51M | $4.99M | $4.38M | $4.63M | $5.00M | $5.43M |
| Long-term debt | — | — | — | — | — | — | — | $11.84M |
| Total debt | — | — | — | — | — | — | — | $11.84M |
| Total liabilities | $30.13M | $30.05M | $29.18M | $28.49M | $17.87M | $17.71M | $15.72M | $15.76M |
| Shareholders' equity | $5.33M | $2.00M | $6.13M | $8.11M | $12.73M | $9.93M | $13.58M | $17.64M |
| Net debt | — | — | — | — | — | — | — | $7.24M |
| Shares outstanding | 1.62M | 743,418 | 589,639 | 8.40M | 8.01M | 4.69M | 4.13M | 74.33M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.57M | -$4.95M | -$4.95M | -$4.22M | -$4.45M | -$4.53M | -$6.96M | -$7.73M |
| Capital expenditure | $751,000 | $208,000 | $547,000 | $34,000 | $246,000 | $198,000 | $1.50M | $537,000 |
| Free cash flow | -$6.32M | -$5.15M | -$5.49M | -$4.25M | -$4.70M | -$4.72M | -$8.46M | -$8.27M |
| Investing cash flow | -$2.11M | $461,000 | -$447,000 | -$4.04M | $240,000 | $576,000 | $2.58M | -$6.94M |
| Financing cash flow | $9.69M | $3.06M | $4.90M | $11.21M | $8.92M | $4.07M | $4.50M | -$9.21M |
| Depreciation & amortization | $800,000 | $800,000 | $800,000 | $800,000 | $800,000 | $800,000 | $800,000 | $800,000 |
| Stock-based compensation | $426,000 | $1.04M | $427,000 | $1.50M | $1.77M | $1.58M | $158,000 | $2.48M |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.